{
    "hands_on_practices": [
        {
            "introduction": "The first essential skill in trial design is to evaluate the statistical power of a proposed study. This exercise requires you to compute the power for a trial with a fixed sample size, effect size, and variability, starting from first principles . Mastering this calculation provides a concrete understanding of how study parameters collectively determine the probability of detecting a true effect.",
            "id": "4992615",
            "problem": "A parallel-group comparative study is being planned to evaluate whether a new therapy improves a continuous clinical endpoint relative to a control therapy. The primary endpoint is measured on a scale where the Minimal Clinically Important Difference (MCID) is defined to be $3$ units. Historical data from large registries support modeling the endpoint as approximately normally distributed with a common, known population standard deviation $\\sigma=12$ units across arms, and independent measurements across participants. The design uses equal allocation with $n_{T}=120$ participants in the treatment arm and $n_{C}=120$ participants in the control arm. The null hypothesis is $H_{0}:\\mu_{T}-\\mu_{C}=0$ and the alternative is two-sided, $H_{1}:\\mu_{T}-\\mu_{C}\\neq 0$, with a Type I error rate $\\alpha=0.05$.\n\nUsing only core definitions and first principles (Type I error, Type II error, and statistical power), and properties of independent normal samples and their sample means, compute the statistical power to detect a true mean difference equal to the MCID of $3$ units under this design. Express the power as a decimal in the interval $[0,1]$, and round your answer to four significant figures. Then, interpret the result in clinical terms (e.g., the likelihood of detecting a difference of the MCID under this design).",
            "solution": "The power of a statistical test is the probability, under a specified true parameter value, of rejecting the null hypothesis. Equivalently, if $\\beta$ denotes the Type II error rate (the probability of failing to reject the null hypothesis when a specified alternative is true), then power is $1-\\beta$. For a two-sample comparison of means with independent observations and a common, known standard deviation, the sampling distribution of the difference in sample means arises from properties of the normal distribution and the independence of samples.\n\nLet $\\bar{X}_{T}$ and $\\bar{X}_{C}$ denote the sample means in the treatment and control arms, respectively. Under the model assumptions, each participantâ€™s endpoint is normally distributed with mean $\\mu_{T}$ or $\\mu_{C}$ and common known standard deviation $\\sigma=12$. The sample means satisfy\n$$\n\\bar{X}_{T}\\sim \\mathcal{N}\\!\\left(\\mu_{T},\\frac{\\sigma^{2}}{n_{T}}\\right),\\qquad \\bar{X}_{C}\\sim \\mathcal{N}\\!\\left(\\mu_{C},\\frac{\\sigma^{2}}{n_{C}}\\right),\n$$\nwith independence between arms. Therefore, the difference $\\bar{X}_{T}-\\bar{X}_{C}$ is normal with mean $\\mu_{T}-\\mu_{C}$ and variance\n$$\n\\operatorname{Var}(\\bar{X}_{T}-\\bar{X}_{C})=\\frac{\\sigma^{2}}{n_{T}}+\\frac{\\sigma^{2}}{n_{C}}.\n$$\nDefine the test statistic\n$$\nZ=\\frac{\\bar{X}_{T}-\\bar{X}_{C}}{\\sqrt{\\frac{\\sigma^{2}}{n_{T}}+\\frac{\\sigma^{2}}{n_{C}}}}.\n$$\nUnder $H_{0}:\\mu_{T}-\\mu_{C}=0$, $Z$ follows a standard normal distribution, $Z\\sim \\mathcal{N}(0,1)$. For a two-sided test with Type I error $\\alpha=0.05$, the rejection region is $|Z|z_{1-\\alpha/2}$, where $z_{1-\\alpha/2}$ is the $(1-\\alpha/2)$ quantile of the standard normal distribution. Numerically, $z_{1-\\alpha/2}=\\Phi^{-1}(0.975)\\approx 1.959963984540054$, where $\\Phi$ denotes the standard normal cumulative distribution function.\n\nUnder the alternative in which the true mean difference equals the Minimal Clinically Important Difference, $\\delta=\\mu_{T}-\\mu_{C}=3$, the distribution of $Z$ is normal with mean\n$$\n\\mu_{Z}=\\frac{\\delta}{\\sqrt{\\frac{\\sigma^{2}}{n_{T}}+\\frac{\\sigma^{2}}{n_{C}}}}\n$$\nand unit variance. With $n_{T}=n_{C}=120$ and $\\sigma=12$,\n$$\n\\sqrt{\\frac{\\sigma^{2}}{n_{T}}+\\frac{\\sigma^{2}}{n_{C}}}=\\sigma\\sqrt{\\frac{1}{n_{T}}+\\frac{1}{n_{C}}}=12\\sqrt{\\frac{1}{120}+\\frac{1}{120}}=12\\sqrt{\\frac{2}{120}}=12\\sqrt{\\frac{1}{60}}=\\frac{12}{\\sqrt{60}}.\n$$\nHence,\n$$\n\\mu_{Z}=\\frac{3}{12/\\sqrt{60}}=\\frac{\\sqrt{60}}{4}.\n$$\nThe power is the probability, under $Z\\sim \\mathcal{N}(\\mu_{Z},1)$, that $|Z|z_{1-\\alpha/2}$:\n$$\n\\text{Power}=\\Pr\\!\\left(Zz_{1-\\alpha/2}\\right)+\\Pr\\!\\left(Z-z_{1-\\alpha/2}\\right)=\\left[1-\\Phi\\!\\left(z_{1-\\alpha/2}-\\mu_{Z}\\right)\\right]+\\Phi\\!\\left(-z_{1-\\alpha/2}-\\mu_{Z}\\right).\n$$\nSubstitute the numerical values. First, compute $\\mu_{Z}=\\sqrt{60}/4\\approx 1.9364916731037085$. Then\n$$\nz_{1-\\alpha/2}-\\mu_{Z}\\approx 1.959963984540054-1.9364916731037085\\approx 0.0234723114363455,\n$$\nand\n$$\n-z_{1-\\alpha/2}-\\mu_{Z}\\approx -1.959963984540054-1.9364916731037085\\approx -3.8964556576437625.\n$$\nEvaluate the standard normal cumulative probabilities:\n$$\n\\Phi\\!\\left(0.0234723114\\right)\\approx 0.5093546932,\\qquad \\Phi\\!\\left(-3.8964556576\\right)\\approx 0.0000486.\n$$\nTherefore,\n$$\n\\text{Power}\\approx \\left[1-0.5093546932\\right]+0.0000486\\approx 0.4906453068+0.0000486\\approx 0.4906939.\n$$\nRounded to four significant figures, the power is $0.4907$.\n\nClinical interpretation: With $n_{T}=n_{C}=120$, $\\alpha=0.05$ two-sided, and a true mean difference equal to the Minimal Clinically Important Difference of $3$ units, the probability of detecting and declaring a statistically significant difference is approximately $0.4907$. In clinical terms, this design has slightly less than even odds of detecting a difference as large as the MCID; equivalently, the Type II error rate at the MCID is approximately $1-0.4907\\approx 0.5093$. If reliably detecting the MCID is a key objective, a larger sample size or a design change would be warranted to increase the power.",
            "answer": "$$\\boxed{0.4907}$$"
        },
        {
            "introduction": "While evaluating the power of a given design is crucial, the more common task is to determine the necessary sample size $n$ to achieve a target power. This practice challenges you to derive the sample size formula from the definitions of Type I and II errors and then apply it to a practical scenario . This skill is the cornerstone of prospective study planning, ensuring your trial is adequately provisioned for success.",
            "id": "4992656",
            "problem": "A two-arm Randomized Controlled Trial (RCT) is planned to compare an antihypertensive drug against placebo with equal allocation. The primary endpoint is the change in systolic blood pressure, measured in millimeters of mercury. Investigators will use a two-sided hypothesis test of the difference in population means with type I error rate $\\alpha = 0.05$. Assume individual patient outcomes within each arm are independent and identically distributed, approximately normal, with a common and known standard deviation $\\sigma = 10$ millimeters of mercury. The clinically meaningful difference to detect is a true mean reduction in the treatment arm relative to placebo of $\\delta = 4$ millimeters of mercury. The design target is statistical power $1 - \\beta = 0.80$.\n\nStarting from the definitions of type I error, type II error, and statistical power, and the distribution of the standardized difference in sample means under the null and under a fixed alternative, derive an expression for the required per-arm sample size for a two-sided test with equal allocation. Then compute the minimal integer number of participants per arm required to attain power at least $0.80$ for $\\delta = 4$, $\\sigma = 10$, and $\\alpha = 0.05$. Provide the final answer as a single integer giving the required per-arm sample size.",
            "solution": "The problem requires deriving the per-arm sample size formula for a two-sided, two-sample test with equal allocation, and then computing the required sample size for the given parameters.\n\n**Derivation:**\nLet $\\mu_1$ and $\\mu_2$ be the population mean changes for the placebo and treatment arms, respectively. The hypotheses are $H_0: \\mu_1 - \\mu_2 = 0$ and $H_a: \\mu_1 - \\mu_2 \\neq 0$. The test statistic is based on the difference in sample means, $\\bar{X}_1 - \\bar{X}_2$. With equal per-arm sample size $n$ and a common known standard deviation $\\sigma$, the sampling distribution of the difference is:\n$$ \\bar{X}_1 - \\bar{X}_2 \\sim \\mathcal{N}\\left(\\mu_1 - \\mu_2, \\frac{2\\sigma^2}{n}\\right) $$\nUnder $H_0$, the test statistic $Z = \\frac{\\bar{X}_1 - \\bar{X}_2}{\\sqrt{2\\sigma^2/n}}$ follows a standard normal distribution, $\\mathcal{N}(0, 1)$. For a two-sided test with Type I error rate $\\alpha$, we reject $H_0$ if $|Z| > z_{1-\\alpha/2}$.\n\nStatistical power ($1-\\beta$) is the probability of rejecting $H_0$ given a specific true difference $\\delta = \\mu_1 - \\mu_2$. Under this alternative, we can relate the sampling distribution to a standard normal variable $Z' \\sim \\mathcal{N}(0,1)$:\n$$ \\frac{(\\bar{X}_1 - \\bar{X}_2) - \\delta}{\\sqrt{2\\sigma^2/n}} = Z' \\implies \\bar{X}_1 - \\bar{X}_2 = \\delta + Z' \\sqrt{\\frac{2\\sigma^2}{n}} $$\nPower is the probability that the observed difference falls in the rejection region. Assuming $\\delta > 0$, the power is dominated by the upper tail of the rejection region:\n$$ 1 - \\beta \\approx P\\left(\\bar{X}_1 - \\bar{X}_2 > z_{1-\\alpha/2}\\sqrt{\\frac{2\\sigma^2}{n}} \\;\\middle|\\; \\mu_1 - \\mu_2 = \\delta \\right) $$\nSubstituting the expression for $\\bar{X}_1 - \\bar{X}_2$:\n$$ 1 - \\beta \\approx P\\left(\\delta + Z'\\sqrt{\\frac{2\\sigma^2}{n}} > z_{1-\\alpha/2}\\sqrt{\\frac{2\\sigma^2}{n}}\\right) = P\\left(Z' > z_{1-\\alpha/2} - \\frac{\\delta}{\\sqrt{2\\sigma^2/n}}\\right) $$\nLet $\\Phi$ be the standard normal CDF. This implies $1 - \\beta \\approx 1 - \\Phi\\left(z_{1-\\alpha/2} - \\frac{\\delta\\sqrt{n}}{\\sigma\\sqrt{2}}\\right)$. For this to hold, the argument of $\\Phi$ must be approximately equal to the quantile $z_{\\beta} = -z_{1-\\beta}$.\n$$ -z_{1-\\beta} \\approx z_{1-\\alpha/2} - \\frac{\\delta\\sqrt{n}}{\\sigma\\sqrt{2}} $$\nRearranging to solve for $n$:\n$$ \\frac{\\delta\\sqrt{n}}{\\sigma\\sqrt{2}} \\approx z_{1-\\alpha/2} + z_{1-\\beta} $$\n$$ n \\approx \\frac{2\\sigma^2(z_{1-\\alpha/2} + z_{1-\\beta})^2}{\\delta^2} $$\nThis is the required formula.\n\n**Calculation:**\nWe are given:\n- $\\alpha = 0.05 \\implies z_{1-\\alpha/2} = z_{0.975} \\approx 1.960$\n- $1 - \\beta = 0.80 \\implies z_{1-\\beta} = z_{0.80} \\approx 0.842$\n- $\\sigma = 10$ mmHg\n- $\\delta = 4$ mmHg\n\nSubstituting these values into the derived formula:\n$$ n = \\frac{2(10)^2(1.960 + 0.842)^2}{(4)^2} = \\frac{200 \\times (2.802)^2}{16} = \\frac{200 \\times 7.851204}{16} \\approx 98.14 $$\nSince the number of participants must be an integer and the power must be *at least* 0.80, we must round the calculated value of $n$ up to the next whole number.\nThus, the minimal required sample size per arm is 99.",
            "answer": "$$ \\boxed{99} $$"
        },
        {
            "introduction": "Power calculations are only as reliable as their inputs, which are often uncertain estimates. This advanced practice introduces sensitivity analysis, a vital tool for assessing a trial's robustness by examining how power changes under different plausible scenarios for effect size $\\delta$ and variability $\\sigma$ . By determining the 'worst-case' power, you learn to design studies that are resilient to the inherent uncertainties of clinical research.",
            "id": "4992685",
            "problem": "A two-arm randomized controlled trial in hypertension will compare the mean reduction in systolic blood pressure between an investigational drug and usual care. Let the true mean reduction difference be $\\delta$ (drug minus control), and assume patient-level outcomes are independently and identically distributed as normal with a common standard deviation $\\sigma$ in both arms. Equal allocation is used with $n=100$ patients per arm. The primary analysis will test the superiority null hypothesis $H_{0}:\\delta=0$ versus the two-sided alternative $H_{1}:\\delta\\neq 0$ at a Type I error rate $\\alpha=0.05$ using a large-sample Wald test based on the difference in sample means.\n\nThe design team has specified baseline planning values $\\delta_{0}=5$ (millimeters of mercury) and $\\sigma_{0}=12$ (millimeters of mercury), but acknowledges uncertainty in these parameters. To assess robustness, conduct a sensitivity analysis of statistical power with respect to simultaneous variation of $\\sigma$ and $\\delta$ by $\\pm 20\\%$ around their baselines. Specifically, treat $\\delta$ and $\\sigma$ as uncertain within the ranges $\\delta\\in[0.8\\delta_{0},\\,1.2\\delta_{0}]$ and $\\sigma\\in[0.8\\sigma_{0},\\,1.2\\sigma_{0}]$, and consider all joint combinations in these ranges.\n\nStarting from the fundamental definitions of Type I error, Type II error, and power, and from the sampling distribution of the difference in sample means under the true $\\delta\\neq 0$, derive the power as a function of $\\sigma$ and $\\delta$. Then, determine the worst-case (minimum) power over the stated joint ranges. Report that single worst-case power value as a decimal in the unitless probability scale. Round your final numerical answer to four significant figures.\n\nIn addition, briefly explain the implications of your sensitivity result for robust trial design in this medical context, grounded in first principles and without assuming any formulas not derived from those principles.",
            "solution": "The problem requires a derivation of the power function, and then finding the worst-case (minimum) power over a specified range of uncertainty for the effect size $\\delta$ and standard deviation $\\sigma$.\n\n**Power Function Derivation:**\nLet $\\delta$ be the true mean difference and $\\sigma$ be the true common standard deviation. With a sample size of $n=100$ per arm, the estimator for the difference, $\\hat{\\delta} = \\bar{X}_{drug} - \\bar{X}_{control}$, follows a normal distribution: $\\hat{\\delta} \\sim \\mathcal{N}(\\delta, \\frac{2\\sigma^2}{n})$.\nThe two-sided test of $H_0: \\delta=0$ at significance level $\\alpha=0.05$ rejects the null hypothesis if $|\\hat{\\delta}| > z_{1-\\alpha/2}\\sqrt{\\frac{2\\sigma^2}{n}}$, where $z_{1-\\alpha/2} = z_{0.975} \\approx 1.95996$.\nThe power is the probability of this event occurring when the true difference is $\\delta$:\n$$ \\text{Power}(\\delta, \\sigma) = P\\left( |\\hat{\\delta}| > z_{1-\\alpha/2} \\sigma\\sqrt{\\frac{2}{n}} \\;\\Bigg|\\; \\delta, \\sigma \\right) $$\nThis can be expressed using the standard normal cumulative distribution function $\\Phi$:\n$$ \\text{Power}(\\delta, \\sigma) = \\Phi\\left(\\frac{|\\delta|}{\\sigma}\\sqrt{\\frac{n}{2}} - z_{1-\\alpha/2}\\right) + \\Phi\\left(-\\frac{|\\delta|}{\\sigma}\\sqrt{\\frac{n}{2}} - z_{1-\\alpha/2}\\right) $$\nThis is the power as a function of $\\sigma$ and $\\delta$.\n\n**Worst-Case Power Calculation:**\nPower is a monotonically increasing function of the standardized effect size $\\frac{|\\delta|}{\\sigma}$. To find the minimum power, we must find the minimum value of this ratio over the specified ranges.\nThe ranges are:\n- $\\delta \\in [0.8\\delta_0, 1.2\\delta_0] = [0.8 \\times 5, 1.2 \\times 5] = [4, 6]$ mmHg.\n- $\\sigma \\in [0.8\\sigma_0, 1.2\\sigma_0] = [0.8 \\times 12, 1.2 \\times 12] = [9.6, 14.4]$ mmHg.\n\nThe ratio $\\frac{|\\delta|}{\\sigma}$ is minimized by taking the smallest possible numerator ($|\\delta|_{min} = 4$) and the largest possible denominator ($\\sigma_{max} = 14.4$).\nThe minimum standardized effect is $\\frac{4}{14.4} = \\frac{1}{3.6}$.\n\nWe compute the power for this worst-case scenario with $n=100$ and $z_{0.975} \\approx 1.95996$. The key term is:\n$$ \\frac{|\\delta|}{\\sigma}\\sqrt{\\frac{n}{2}} = \\frac{4}{14.4}\\sqrt{\\frac{100}{2}} = \\frac{1}{3.6}\\sqrt{50} \\approx 1.964185 $$\nSubstitute this into the power formula:\n$$ \\text{Power}_{min} = \\Phi(1.964185 - 1.95996) + \\Phi(-1.964185 - 1.95996) $$\n$$ \\text{Power}_{min} = \\Phi(0.004225) + \\Phi(-3.924145) $$\nUsing a standard normal calculator:\n$$ \\text{Power}_{min} \\approx 0.501685 + 0.000043 = 0.501728 $$\nRounding to four significant figures, the worst-case power is $0.5017$.\n\n**Implications for Robust Trial Design:**\nThe sensitivity analysis reveals that the statistical power of the proposed trial is highly fragile to the initial planning assumptions. While the power at the baseline values ($\\delta=5, \\sigma=12$) is high (approx. 84%), a plausible unfavorable deviation in these parameters causes the power to plummet to approximately 50%. A power of 50% is equivalent to a coin toss, meaning the trial would have only a 50/50 chance of detecting a true therapeutic effect under this scenario. Conducting a trial with such a high risk of being inconclusive is scientifically and ethically untenable, as it wastes resources and exposes subjects to risk without a reasonable probability of generating useful knowledge. A robust design would maintain adequate power (e.g., $\\ge 80\\%$) across a range of plausible scenarios. This analysis implies that the proposed sample size of $n=100$ per arm is insufficient. The trial should be re-designed with a larger sample size, calibrated to achieve sufficient power even under this identified worst-case scenario.",
            "answer": "$$\n\\boxed{0.5017}\n$$"
        }
    ]
}